The Russian Federal Medical and Biological Agency has obtained a product license for the import-substituting radiopharmaceutical “Rakurs” (223Ra). This medication is used in radioisotope therapy to treat patients with castration-resistant prostate cancer and bone metastases.
The innovative product was developed at the Federal Scientific and Clinical Center for Medical Radiology and Oncology of Russian Federal Medical and Biological Agency in the city of Dimitrovgrad with the active involvement of experts from Research Institute of Nuclear Reactors, State Scientific Centre, Joint-Stock Company (RIAR JSC of Rosatom Scientific Division). The medication is produced using Russian-sourced starting materials.
“This is another significant achievement for our team in the field of nuclear medicine. In close collaboration with colleagues from the Federal Scientific and Clinical Center for Medical Radiology and Oncology, we have developed a medication with immense potential. Each stage of this collaborative effort required experts from both organizations to find innovative solutions, combine scientific expertise with effective techniques. We are headed in the right direction, our cooperation continues”, pointed out Alexander Tuzov, Director of RIAR JSC.
